《中国期刊全文数据库》收录期刊
《中国核心期刊(遴选)数据库》收录期刊
《中文科技期刊数据库》收录期刊
Original article

Expression of S100A7 in intrahepatic cholangiocarcinoma and its clinical significance

  • LU Xiaoliang ,
  • WU Bin ,
  • CHEN Keji ,
  • LI Aijun ,
  • FAN Fei
Expand
  • Department of The Third Ward of Special Treatment, Eastern Hepatobiliary Surgery Hospital, Navy Medical University, Shanghai 200438, China

Received date: 2021-01-07

  Online published: 2021-05-18

Abstract

Objective To observe the expression of S100A7 in intrahepatic cholangiocarcinoma (ICC) and its clinical significance. Methods Tissue specimens from 30 cases of pathologically proven ICC were collected in the Eastern Hepatobiliary Surgery Hospital from January 2018 to January 2020. The expression of S100A7 in ICC tissue was analyzed by immunohistochemistry, Western blotting and PCR. Results The S100A7 level expressed in ICC tissue was significantly higher than that in para-carcinoma (50% vs. 10%, P<0.05).The expression of S100A7 was correlated with the depth of tumor invasion, lymph node metastasis and TNM stage (all P<0.05), but not correlated with the patient's sex, age, lymphatic invasion, tumor differentiation and distant metastasis. Conclusion S100A7 is overexpressesd in ICC, which is helpful to evaluate the prognosis of patients with ICC.

Cite this article

LU Xiaoliang , WU Bin , CHEN Keji , LI Aijun , FAN Fei . Expression of S100A7 in intrahepatic cholangiocarcinoma and its clinical significance[J]. Surgical Research and New Technique, 2021 , 10(1) : 4 -8 . DOI: 10.3969/j.issn.2095-378X.2021.01.002

References

[1] Akateh C, Ejaz AM, Pawlik TM, et al, Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma[J]. World J Hepatol, 2020,12(10):693-708.
[2] Khan AS, Dageforde LA, Cholangiocarcinoma[J]. Surg Clin North Am, 2019,99(2):315-335.
[3] Massarweh NN, El-Serag HB, Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma[J]. Cancer Controll, 2017,24(3):1073274817729245.
[4] Blechacz B, Komuta M,Roskams T, alet, Clinical diagnosis and staging of cholangiocarcinoma[J]. Nat Rev Gastroenterol Hepatol,2011,8(9):512-522.
[5] Thorsen MK, Quiroz F, Lawson TL, et al.Primary biliary carcinoma: CT evaluation[J]. Radiology, 1984,152(2):479-483.
[6] Yang XQ, Xu YF, Guo S, et al.Clinical significance of nerve growth factor and tropomyosin-receptor-kinase signaling pathway in intrahepatic cholangiocarcinoma[J]. WJG, 2014,20(14):4076-4084.
[7] Ariizumi S, Kotera Y, Katagiri S, et al.Long-term survival of patients with cholangiolocellular carcinoma after curative hepatectomy[J]. Ann Surg Oncol, 2014,21(Suppl 3):451-458.
[8] Luo X, Yuan L, Wang Y, et al.Survival outcomes and prognostic factors of surgical therapy for all potentially resectable intrahepatic cholangiocarcinoma: a large single-center cohort study[J]. J Gastrointest Surg, 2014,18(3):562-572.
[9] He CB,Zhang Y, Song Y, et al.Preoperative CEA levels are supplementary to CA19-9 levels in predicting prognosis in patients with resectable intrahepatic cholangiocarcinoma[J]. Cancer, 2018,9(17):3117-3128.
[10] Rangaraj A,Ye L, Sanders AJ, et al.Molecular and cellular impact of psoriasin (S100A7) on the healing of human wounds[J]. Exp Ther Med,2017,13(5):2151-2160.
[11] Donato R.S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles[J]. Int J Biochem Cell Biol, 2001,33(7):637-668.
[12] De Cid R, Riveira-Munoz E, Zeeuwen Patrick LJM, et al.Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis[J]. Nat Gene ,2009,41(2):211-215.
[13] Bresnick AR.S100 proteins as therapeutic targets[J]. Biophys Rev, 2018,10(6):1617-1629.
[14] Brodersen DE, Nyborg J, Kjeldgaard M.Zinc-binding site of an S100 protein revealed. Two crystal structures of Ca2+-bound human psoriasin (S100A7) in the Zn2+-loaded and Zn2+-free states[J]. Biochemistry, 1999,38(6):1695-1704.
[15] Fan JJ, Hsu WH, Lee KH,et al.Dietary flavonoids luteolin and quercetin inhibit migration and invasion of squamous carcinoma through reduction of Src/Stat3/S100A7 signaling[J]. Antioxidants (Basel), 2019,8(11):557.
[16] Tian T,Li XK,Hua Z, et al.S100A7 promotes the migration, invasion and metastasis of human cervical cancer cells through epithelial-mesenchymal transition[J]. Oncotarget, 2017,8(15):24964-24977.
[17] Sakurai M, Miki Y, Takagi K, et al.Interaction with adipocyte stromal cells induces breast cancer malignancy via S100A7 upregulation in breast cancer microenvironment[J]. Breast Cancer Res,2017,19(1):70.
[18] Wang R, Li YG, Hu Enze HU, et al.S100A7 promotes lung adenocarcinoma to squamous carcinoma transdifferentiation, and its expression is differentially regulated by the Hippo-YAP pathway in lung cancer cells[J]. Oncotarget, 2017,8(15):24804-24814.
[19] Sneh A, Deol YS, Ganju A, et al.Differential role of psoriasin (S100A7) in estrogen receptor alpha positive and negative breast cancer cells occur through actin remodeling[J]. Breast Cancer Res Treat, 2013,138(3):727-739.
[20] Deol YS, Nasser MW, Yu L, et al.Tumor-suppressive effects of psoriasin (S100A7) are mediated through the beta-catenin/T cell factor 4 protein pathway in estrogen receptor-positive breast cancer cells[J]. J Biol Chem, 2011,286(52):44845-44854.
[21] Fan F, Lu JJ, Yu WL,et al.MicroRNA-26b-5p regulates cell proliferation, invasion and metastasis in human intrahepatic cholangiocarcinoma by targeting S100A7[J]. Oncol Lett,2018,15(1):386-392.
Outlines

/